An Immune-Metabolic Signature Reveals Prognostic Stratification and Tumor Microenvironment Features in Breast Cancer.
- 1Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
- 2Scientific Research Center, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, China.
Abstract
Breast cancer progression reflects coupled immune and metabolic reprogramming, but biomarkers that capture this interplay and provide additional prognostic information beyond routine clinicopathological assessment remain limited. We developed an 11-gene immune-metabolic risk Score in TCGA-BRCA (n = 1099) by integrating C7 immune signatures and KEGG metabolic pathways through Cox and LASSO-Cox modeling. The fixed model was applied without retraining to three public cohorts and an independent institutional cohort of 146 patients from Harbin Medical University Cancer Hospital. The score consistently stratified overall survival across independent cohorts and provided additional prognostic information beyond conventional clinicopathological variables. Integrative analyses showed that high-risk tumors were characterized by enhanced cell-cycle and metabolic activation, reduced lymphocyte-associated immune features, and monocytic-lineage enrichment. At single-cell resolution, high-score cancer-associated fibroblasts exhibited enhanced extracellular-matrix remodeling, inflammatory iCAF activity, and TGF-β-associated immunosuppressive programs. In an exploratory pembrolizumab-containing cohort, lower pretreatment scores were associated with pathological complete response and immune-active transcriptional programs; however, these findings do not establish the score as a predictive biomarker for immunotherapy benefit. The 11-gene immune-metabolic risk Score provides complementary prognostic stratification beyond conventional clinical variables and characterizes a stromal-remodeled immune-metabolic state associated with adverse breast cancer outcomes.
Related
- Transcription factor-driven metabolic stratification reveals glycolytic and lipogenic subtypes with distinct prognostic and functional features in pancreatic cancer
- The DNA mismatch repair landscape in pancreatic adenocarcinoma: a novel prognostic signature with implications for immune microenvironment and chemotherapy response.
- Evaluation of the Diagnostic and Prognostic Potential, and Correlation with the Tumor Immune Microenvironment of a Six-miRNA Signature Associated with Platinum Sensitivity in Patients with Early-Stage Non-Small-Cell Lung Cancer
- Development and validation of a ferroptosis and metabolic reprogramming gene signature for risk stratification in bladder urothelial carcinoma: A retrospective multicohort study.
- An Eight-Gene Metabolic Prognostic Signature in Head and Neck Squamous Cell Carcinoma: Cross-Cohort Evaluation, Single-Cell Analysis, and Preliminary Functional Evaluation of PYGL and G6PD.
BibTeX
@article{dong2026immunemetabolic,
title = {{An Immune-Metabolic Signature Reveals Prognostic Stratification and Tumor Microenvironment Features in Breast Cancer.}},
author = {Sijia Dong and Wenxiao Xu and Shan Liu and Kun Zhang and Kaihong Deng and Zhigao Li and He Ren},
journal = {Cancer medicine},
year = {2026},
month = nov,
doi = {10.1002/cam4.72465},
url = {https://europepmc.org/article/MED/42972983},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - An Immune-Metabolic Signature Reveals Prognostic Stratification and Tumor Microenvironment Features in Breast Cancer.
AU - Sijia Dong
AU - Wenxiao Xu
AU - Shan Liu
AU - Kun Zhang
AU - Kaihong Deng
AU - Zhigao Li
AU - He Ren
PY - 2026
DA - 2026/11/01
JO - Cancer medicine
DO - 10.1002/cam4.72465
UR - https://europepmc.org/article/MED/42972983
AB - Breast cancer progression reflects coupled immune and metabolic reprogramming, but biomarkers that capture this interplay and provide additional prognostic information beyond routine clinicopathological assessment remain limited. We developed an 11-gene immune-metabolic risk Score in TCGA-BRCA (n = 1099) by integrating C7 immune signatures and KEGG metabolic pathways through Cox and LASSO-Cox modeling. The fixed model was applied without retraining to three public cohorts and an independent institutional cohort of 146 patients from Harbin Medical University Cancer Hospital. The score consistently stratified overall survival across independent cohorts and provided additional prognostic information beyond conventional clinicopathological variables. Integrative analyses showed that high-risk tumors were characterized by enhanced cell-cycle and metabolic activation, reduced lymphocyte-associated immune features, and monocytic-lineage enrichment. At single-cell resolution, high-score cancer-associated fibroblasts exhibited enhanced extracellular-matrix remodeling, inflammatory iCAF activity, and TGF-β-associated immunosuppressive programs. In an exploratory pembrolizumab-containing cohort, lower pretreatment scores were associated with pathological complete response and immune-active transcriptional programs; however, these findings do not establish the score as a predictive biomarker for immunotherapy benefit. The 11-gene immune-metabolic risk Score provides complementary prognostic stratification beyond conventional clinical variables and characterizes a stromal-remodeled immune-metabolic state associated with adverse breast cancer outcomes.
SN - 2045-7634
ER -